Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-577-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-15"^^xsd:date2
dcterms:Is Part Of	lp_eu:Falsified medicinal products (debate)2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20110215.29.2-577-000"2
lpv:hasSubsequent	lp_eu:2011-02-15-Speech-2-578-0002
lpv:speaker	lp:Elżbieta Katarzyna Łukacijewska2
lpv:spokenAs	substitute; Delegation for relations with the People's Republic of China (2009-09-16--2014-06-30)3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 member; REGI (2009-09-14--2012-01-18)3 member; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 substitute; ENVI (2009-07-16--2012-01-18)3 member; EPP (2009-07-14--2014-06-30)3 unknown; Platforma Obywatelska (2009-07-14--2014-06-30)3
lpv:translated text	"Madam President, according to the World Health Organisation, around 10% of the global pharmaceutical market is accounted for by counterfeit medicinal products. It is hard to estimate the exact scale of the problem in the individual Member States of the European Union, but in Poland in 2009 alone, for example, customs officers confiscated over 100 000 falsified products. Apart from falsified medicines, the problems which patients face include a lack of reliable information on the contents of packaging, and also the issue of repackaging, during which the contents may change. It is also very important for patients to be able to obtain reliable information on the Internet. Unfortunately, as well as much information which is genuine, there is a lot of information on the Internet which is false. Against this background, it is important to introduce a system for monitoring and checking medicines, which will provide patients with reliable information. We are aware, however, that even the best regulations will not bring about the anticipated effect if they include no provisions for appropriate penalties for entities which put counterfeit medicines into circulation. Today’s debate is therefore extremely important, as is the introduction of regulations which not only prevent the distribution of counterfeit medicines and put in place a monitoring system, but which, above all, impose penalties on the manufacturers of fakes. Numbers of counterfeit medicinal products will only be reduced and their use made safer if measures of this kind are taken. Finally, I would like to congratulate the rapporteur, Mrs Matias, on a good report. I am aware that it will not solve every problem, but it is a major step towards increasing patient safety."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph